《2016年欧洲心脏病学会/欧洲动脉粥样硬化学会血脂异常管理指南》解读
陈涛,袁祖贻
摘要(Abstract)：
<正>2016年8月,欧洲心脏病学会(European Society of Cardiology,ESC)和欧洲动脉粥样硬化学会(European Atherosclerosis Society,EAS)联合发布了欧洲血脂异常管理指南(以下简称《2016年指南》)[1]。《2016年指南》以《2011年ESC/EAS血脂异常管理指南》(以下简称《2011年指南》)[2]为基
关键词(KeyWords)： 血脂异常;指南解读
基金项目(Foundation):
作者(Author): 陈涛,袁祖贻
参考文献(References)：
- [1]Catapano AL,Graham I,De Backer G,et al.2016 ESC/EAS guidelines for the management of dyslipidaemias:The task force for the management of dyslipidaemias of the European Society of Cardiology(ESC)and European Atherosclerosis Society(EAS)developed with the special contribution of the European Assocciation for Cardiovascular Prevention&Rehabilitation(EACPR).Eur Heart J,2016.[Epub ahead of print]
- [2]Reiner Z,Catapano AL,De Backer G,et al.ESC/EAS guidelines for the management of dyslipidaemias:the task force for the management of dyslipidaemias of the European Society of Cardiology(ESC)and the European Atherosclerosis Society(EAS).Eur Heart J,2011,32(14):1769-1818.
- [3]Stone NJ,Robinson JG,Lichtenstein AH,et al.2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults:a report of the American College of Cardiology/American Heart Association task force on practice guidelines.J Am Coll Cardiol,2014,63(25 Pt B):2889-2934.
- [4]Langsted A,Nordestgaard BG.Nonfasting lipids,lipoproteins,and apolipoproteins in individuals with and without diabetes:58 434 individuals from the copenhagen general population study.Clin Chem,2011,57(3):482-489.
- [5]Boden WE,Probstfield JL,Anderson T,et al.Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy.N Engl J Med,2011,365(24):2255-2267.
- [6]Landray MJ,Haynes R,Hopewell JC,et al.Effects of extendedrelease niacin with laropiprant in high-risk patients.N Engl J Med,2014,371(3):203-212.